Investigating how MARCH proteins help target HIV
MARCH Proteins, Members of a Host Protein Family that Targets HIV
This study is looking at special proteins that help the immune system fight HIV, to see how they work and how the virus might get around them, with the hope of finding new ways to help the body better resist HIV infection.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | State University of New York at Buffalo NIH-funded |
| Lab location | 1 site (Amherst, United States) |
| Project ID | NIH-11144106 on NIH RePORTER |
What this research studies
This research focuses on MARCH proteins, which are involved in regulating immune responses and have shown potential in restricting HIV infection. The study aims to understand how these proteins interact with HIV and how the virus may evade this immune response. By examining the mechanisms of MARCH proteins, the research seeks to uncover new insights into their role in blocking HIV from infecting cells. This could lead to the development of novel antiviral therapies that enhance the body's ability to fight HIV.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living with HIV or those at high risk of HIV infection.
Not a fit: Patients who are not infected with HIV or who do not have a risk of HIV exposure may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that improve the immune response against HIV, potentially benefiting patients living with HIV/AIDS.
How similar studies have performed: Previous research has shown that targeting similar mechanisms in viral infections can lead to significant advancements in treatment, suggesting a promising avenue for this approach.
Where this research is happening
Amherst, United States
- State University of New York at Buffalo — Amherst, United States (Active)
Researchers
- Principal investigator: Stavrou, Spyridon — State University of New York at Buffalo
- Study coordinator: Stavrou, Spyridon
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.